Do post-COVID-19 patients need a second dose of the vaccine?

Project specs




Anne-Marie Leech






The Richmond Research Institute compared the level of antibody response to COVID vaccines between those who have and have not previously been infected by the virus to establish their degree of immunity.

Background on the safety measures in place:

Testing for COVID-19 is crucial to understand who is infected and therefore a risk to others by spreading the infection. By repeating these tests over time, we can establish how long the antibodies take to develop and how long immunity may last in each person.

Routine testing of staff, trial volunteers, and visitors began on 19 March 2020. The rigorous testing procedure consists of multiple tests to ensure the results are reliable. This minimizes the risk to all entering the unit.

All staff have been offered a COVID-19 vaccine.

Researcher Profile

Richmond Research Institute is a not-for-profit organisation dedicated to drug safety research to improve and save lives.

Our world-class research aims to explore the usefulness of potential new medicines, assesses the safety of existing medicinal products, and provides the scientific insights to improve strategies for personalised medicines.

Can we map global arms trading through network data…

Global arms trade project funded by the Deutsche Forschungsgemeinschaft in…